The faster way to prioritise the right lead compound.
Mycelium closes the gap between the evidence your team already has and the decision it's waiting to make.
Early access · Prototype in development
Candidate A
92%
Candidate B
74%
Evaluating
Preferred candidate: Candidate A carries higher confidence, lower complexity and lower cost than Candidate B.
What if choosing the next synthesis route was easier?
Mycelium is being built to help chemistry teams evaluate synthesis routes continuously, bringing scientific evidence, route complexity and practical considerations together so teams can focus on making the right decision.
The data arrives every day.
The decision only gets made once a week.
Lab test results land continuously, but candidates only get properly reviewed once a week, at the status call between the CRO and the client.
A compound that's stopped being worth pursuing can sit untouched, still costing time and budget, until someone finally notices.
Two different rhythms
Science runs on a daily rhythm. Decisions run on a weekly one.
Experimental results scattered across notebooks and reports.
Weekly status call
CRO and sponsor, once a week.
Decision
Some evidence is already a week old.
[ The opportunity ]
The evidence already exists.
It's just sitting idle between calls.
The CRO side already generates nearly all of the underlying scientific data; the client side mainly sets the thresholds that define what a good candidate looks like. Mycelium doesn't change how the science gets done. It makes sure what's already being measured gets used the moment it's ready, not just once a week.
Pulling together data, candidates and context from scattered sources.
Continuously scores every candidate against the agreed criteria.
One fewer step between evidence arriving and the candidate being chosen.
The right candidate, the right route.
Candidates are scored against the client's own target profile first. Only those that genuinely clear the bar have their proposed routes ranked against each other. Nothing is generated by the system. Chemists design every candidate and every route themselves. Mycelium organises, scores and ranks what already exists: pharmacology, ADME & safety, and synthetic and route factors, so the recommendation reflects the full picture.
How well a compound does its job: the starting point for any route decision.
Continuous evaluation → Clearer prioritisation → Faster decisions
Every ranking traces back to the measured evidence behind it. Nothing is a black box.
If it hasn't been measured, Mycelium says so. It never fills the gap with a guess.
The moment new data lands, the ranking updates. No more waiting for the next call to find out.
This is a tool for making the evidence clear. The decision stays with the chemist.
Agree the criteria. Mycelium watches the evidence.
You walk in already knowing.
Step 01
Agree the criteria
The target profile and thresholds, set once with the client.
Step 02
Mycelium watches the evidence
Every new lab result is scored and ranked the moment it lands.
Step 03
You walk in already knowing
The status call reviews a live decision, not a data dump built the night before.
Every candidate, ranked, the moment new data arrives. See exactly why a candidate ranks where it does, and which route gets it there fastest.
Candidate ranking
LiveBuilt by people who understand the workflow.
Mycelium is being built within o2h discovery's chemistry practice, led by the team below.
Sunil Shah
Serial entrepreneur in life sciences and technology; co-founded o2h Ventures.
Prashant Shah
Serial entrepreneur in life sciences and tech, active in seed investing across roughly 50 companies.
Andy Morley
25+ years as a medicinal chemist at Sanofi-Aventis and AstraZeneca; author of 55+ publications and patents.
Nilesh Dagia
Leads global operations across o2h's investment, life-science and technology businesses.
Today, Mycelium recommends.
Tomorrow, it starts handling the rest.
Live now
Mycelium continuously scores and ranks candidates and routes against agreed criteria, making the decision behind every ranking obvious and surfacing the insight that matters most.
Early access
Be part of the next decision, not the next status call.
Mycelium is being built for CROs and pharma sponsors who recognise this exact pain from their own weekly calls. Join the waitlist to be notified as the product develops.